AL
Last reporting period 31 Mar, 2024
Updated —
Last price
—
Market cap $B
4.457
Exchange
XNAS - Nasdaq
-15 %
Last period ROE
63%
ROE has increased in 5 years
What is ROE ?
The return on equity ratio shows how much net profit a company earns per unit of equity. To calculate the company's rating, the return on equity adjusted for the average level of financial leverage for 3 years is taken into account. The value of 20% is the benchmark for Eyestock Rating calculation.
See also Alpine Immune
Company Analysis
ALPN valuation, rating, competitors, insights and company profile
Eyestock Rating
ALPN financial analysis by Eyestock methodology
Valuation
ALPN valuation using historical relative method
Statements
ALPN Income Statements, Balance Sheet and Cash Flow Statements
Dividends
ALPN dividend yield and annual dividend
The return on equity ratio shows how much net profit a company earns per unit of equity. To calculate the company's rating, the return on equity adjusted for the average level of financial leverage for 3 years is taken into account. The value of 20% is the benchmark for Eyestock Rating calculation.
Alpine Immune`s ROE for the last twelve months ended 2024-03-31 is -15 %
